Drug Trial Radar · NCT05266807
Fecal Microbiota Transplantation in Clostridioides Difficile Infection First Episode and First Recurrence
Last checked: Nov 20, 2026Latest source record: Jul 10, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
100
Planned (sponsor's estimate)
Start
Mar 15, 2023
Primary completion
Apr 1, 2027
Study completion Jan 31, 2028
Sponsor
- Lead sponsor
- Benoit GueryAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- First posted
- Mar 4, 2022
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The clinical trial aims to evaluate the efficacy of fecal microbiota transplantation (FMT) after standard of care treatment (either vancomycin or fidaxomicin) vs the pragmatic use of standard of care treatment (either vancomycin or fidaxomicin) in severe and non-severe first episode and first recurrence of Clostridioides difficile infection (CDI). Experimental arm: antibiotic treatment (vancomycin or fidaxomicin as initially prescribed per SoC continued for 10 days) followed by FMT by oral capsules (one FMT, i.e. 20 FMT capsules given on 2 consecutive days, and followed by a 2nd FMT in severe CDI). Control Arm: vancomycin or fidaxomicin as initially prescribed per SoC continued for 10 days.
Conditions
- Clostridioides Difficile Infection
Interventions
oral capsulized Fecal Microbiota TransplantationDrug
FMT will be administered per os in the form of capsules containing faeces from a healthy donor. Capsules are manufactured at the CHUV pharmacy (University Hospital of Lausanne, Switzerland)
Vancomycin or FidaxomicinDrug
Vancomycin or Fidaxomicin per os as initially prescribed per SoC
Primary outcomes
What the sponsor says the trial is designed to measure.
- Sustained clinical cure rateTime frame: 8 weeks after study treatment completion
Locations
8 sites in 1 country. Site status is shown where the registry gives one.
Universitätsspital
Basel, Basel, Switzerland · Recruiting
Inselspital Bern
Bern, Canton of Bern, Switzerland · Recruiting
HFR Fribourg - Hôpital cantonal
Fribourg, Canton of Fribourg, Switzerland · Recruiting
Hirslanden Klinik St Anna
Lucerne, Canton of Lucerne, Switzerland · Recruiting
Kantonsspital St Gallen, HOCH
Sankt Gallen, Canton of St. Gallen, Switzerland · Recruiting
CHUV
Lausanne, Canton of Vaud, Switzerland · Recruiting
Universitätsspital Zürich
Zurich, Canton of Zurich, Switzerland · Recruiting
Institut central des hôpitaux
Sion, Valais, Switzerland · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.